Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Excellent Outcome in NPM1- mutated Acute Myeloid Leukemia Patients Receiving Intensified Fludarabine-Based Induction Is Not Affected By Secondary Type Mutations and Other High Risk Aberrations

Paola Minetto, Carola Riva, Enrico Carminati, Ylenia Azzanelli, Francesco Puglisi, Clara Nurra, Giuseppina Fugazza, Antonia Cagnetta, Michele Cea, Roberto Massimo Lemoli, Fabio Guolo

Blood (2024) 144 (Supplement 1): 4239.

https://doi.org/10.1182/blood-2024-198171

Published: 2024

Journal Articles

Deciphering the Immune Microenvironment in Waldenstrom's Macroglobulinemia

Blood (2023) 142 (Supplement 1): 4690.

https://doi.org/10.1182/blood-2023-188408

Published: 2023

Journal Articles

High Efficacy and Feasibility of a Full Pediatric Induction in Adults Aged up to 55 Years with Philadelphia-Negative Acute Lymphoblastic Leukemia

Chiara Vernarecci, Elena Maio, Mattia Montanari, Francesco Puglisi, Clara Nurra, Maurizio Miglino, Nicoletta Colombo, Enrico Carminati, Giada Zecchetti, Maria Chies, Beatrice Ferro, Massimo Zucchetti, Antonia Cagnetta, Michele Cea, Elisabetta Tedone, Roberto Massimo Lemoli, Fabio Guolo, Paola Minetto

Blood (2023) 142 (Supplement 1): 5879.

https://doi.org/10.1182/blood-2023-185082

Published: 2023

Journal Articles

Mutational Burden in High Risk Genes Do Not Affect Remission Rates and MRD Clearance in Elderly AML Patients Receiving CPX-351 Induction

Carola Riva, Paola Minetto, Enrico Carminati, Maria Chies, Chiara Vernarecci, Beatrice Ferro, Elena Maio, Giada Zecchetti, Michela Frello, Maurizio Miglino, Elisabetta Tedone, Nicoletta Colombo, Clara Nurra, Francesco Puglisi, Antonia Cagnetta, Michele Cea, Giuseppina Fugazza, Roberto Massimo Lemoli, Fabio Guolo

Blood (2023) 142 (Supplement 1): 6016.

https://doi.org/10.1182/blood-2023-186555

Published: 2023

Journal Articles

Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

Blood (2023) 141 (21): 2615–2628.

https://doi.org/10.1182/blood.2022019240

Published: 2023

Includes: Supplemental data

Journal Articles

Clonal Hematopoiesis: Exploiting Molecular Landscape of Multiple Myeloma Patients for Choosing the Most Appropriate Therapeutic Strategy

Elisa Gelli, Antonella Laudisi, Claudia Martinuzzi, Debora Soncini, Pamela Becherini, Fabio Guolo, Concetta Conticello, Daniele Derudas, Francesco Di Raimondo, Antonia Cagnetta, Domenico Coviello, Roberto Massimo Lemoli, Michele Cea

Blood (2022) 140 (Supplement 1): 7064–7065.

https://doi.org/10.1182/blood-2022-169263

Published: 2022

Journal Articles

The Multi-Kinases Inhibitor ARQ531 Enhanches Anti-MM Activity of Imids By Dual Deregulation of MAP- and Cyclin-Dependent Kinases Activities

Debora Soncini, Pamela Becherini, Elisa Gelli, Claudia Martinuzzi, Fabio Guolo, Antonino Neri, Antonia Cagnetta, Roberto Massimo Lemoli, Michele Cea

Blood (2022) 140 (Supplement 1): 9929.

https://doi.org/10.1182/blood-2022-169453

Published: 2022

Journal Articles

Prognostic Relevance of Minimal Residual Disease in Therapy Related and Secondary Acute Myeloid Leukemia Receiving CPX-351 or Fludarabine-Based Induction

Fabio Guolo, Paola Minetto, Carola Riva, Chiara Vernarecci, Monica Passannante, Francesca Parodi, Michela Frello, Elena Maio, Beatrice Ferro, Maria Chies, Maurizio Miglino, Elisabetta Tedone, Nicoletta Colombo, Enrico Carminati, Clara Nurra, Francesco Puglisi, Antonia Cagnetta, Michele Cea, Roberto Massimo Lemoli

Blood (2022) 140 (Supplement 1): 8930–8931.

https://doi.org/10.1182/blood-2022-169394

Published: 2022

Journal Articles

Prognostic Impact of Minimal Residual Disease Assessment in Elderly Patients with Secondary Acute Myeloid Leukemia. a Comparison between CPX-351 and Intensified Fludarabine-Based Regimens

Fabio Guolo, Paola Minetto, Marino Clavio, Maurizio Miglino, Riccardo Marcolin, Monica Passannante, Carola Riva, Michela Frello, Chiara Vernarecci, Elisabetta Tedone, Nicoletta Colombo, Enrico Carminati, Girolamo Pugliese, Clara Nurra, Antonia Cagnetta, Michele Cea, Marco Gobbi, Roberto M. Lemoli

Blood (2021) 138 (Supplement 1): 3442.

https://doi.org/10.1182/blood-2021-153060

Published: 2021

Journal Articles

Addition of the Anti-CD33 Monoclonal Antibody Mylotarg to Fludarabine/High Dose Cytarabine - Based Induction Significantly Improves Outcome in Patient Affected By FLT3-ITD Positive Cytogenetically Normal Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1365.

https://doi.org/10.1182/blood-2019-131420

Published: 2019

Journal Articles

A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML

Fabio Guolo, MD, Paola Minetto, MD, Annalisa Kunkl, MD, Elisabetta Tedone, Marino Clavio, MD, Maurizio Miglino, PhD, Fabrizio Caviglia, Nicoletta Colombo, PhD, Antonia Cagnetta, MD, Michele Cea, MD, Filippo Ballerini, MD, Jean Louis Ravetti, MD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD

Blood (2018) 132 (Supplement 1): 5243.

https://doi.org/10.1182/blood-2018-99-118984

Published: 2018

Journal Articles

Erwinia Chrysantemi-Derived L-Asparaginase Strongly Enhances Proteasome Inhibitors Activity By Deregulating Cell Metabolic Programs

Paola Minetto, MD, Debora Soncini, PhD, Fabio Guolo, MD, Samantha Ruberti, BSc, PhD, Veronica Retali, Paola Contini, Nadia Bisso, MD, Nikki Di Felice, MD, Giulia Rivoli, MD, Antonia Cagnetta, MD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD, Michele Cea, MD

Blood (2018) 132 (Supplement 1): 3221.

https://doi.org/10.1182/blood-2018-99-119622

Published: 2018

Journal Articles

Role of Erythropoietin in the Late Anemia of Patients with Chronic Myeloid Leukemia Treated Frontline with Imatinib

Blood (2017) 130 (Supplement 1): 2884.

https://doi.org/10.1182/blood.V130.Suppl_1.2884.2884

Published: 2017

Journal Articles

Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information

Paola Minetto, MD, Fabio Guolo, MD, Marino Clavio, MD, Annalisa Kunkl, MD, Nicoletta Colombo, PhD, Enrico Carminati, Giuseppina Fugazza, Simona Matarese, MD, Daniela Guardo, MD, Filippo Ballerini, MD, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Antonia Cagnetta, MD, Michele Cea, Maurizio Miglino, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 5047.

https://doi.org/10.1182/blood.V130.Suppl_1.5047.5047

Published: 2017

Journal Articles

Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors

Paola Minetto, MD, Debora Soncini, PhD, Antonia Cagnetta, MD, Fabio Guolo, MD, Veronica Retali, Giulia Rivoli, MD, Nadia Bisso, MD, Nikki Di Felice, MD, Maurizio Miglino, PhD, Letizia Canepa, MD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD, Michele Cea

Blood (2017) 130 (Supplement 1): 1796.

https://doi.org/10.1182/blood.V130.Suppl_1.1796.1796

Published: 2017

Journal Articles

SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia

Michele Cea, MD, Antonia Cagnetta, MD, Debora Soncini, PhD, Paola Minetto, MD, Davide Lovera, MD, Fabio Guolo, MD, Nicoletta Colombo, PhD, Filippo Ballerini, MD, Marino Clavio, MD, Maurizio Miglino, PhD, Marco Gobbi, MD, Roberto M Lemoli, MD

Blood (2016) 128 (22): 5222.

https://doi.org/10.1182/blood.V128.22.5222.5222

Published: 2016

Journal Articles

CD38 Deregulation As Strategy to Make Multiple Myeloma Cells More Sensitive to NAD+ Depleting Agents

Michele Cea, MD, Antonia Cagnetta, MD, Debora Soncini, PhD, Paola Minetto, MD, Micaela Bergamaschi, MD, Giulia Rivoli, MD, Letizia Canepa, MD, Marco Gobbi, MD, Roberto M Lemoli, MD

Blood (2016) 128 (22): 5671.

https://doi.org/10.1182/blood.V128.22.5671.5671

Published: 2016

Journal Articles

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment

Yu-Tzu Tai, Chirag Acharya, Gang An, Michele Moschetta, Mike Y. Zhong, Xiaoyan Feng, Michele Cea, Antonia Cagnetta, Kenneth Wen, Hans van Eenennaam, Andrea van Elsas, Lugui Qiu, Paul Richardson, Nikhil Munshi, Kenneth C. Anderson

Blood (2016) 127 (25): 3225–3236.

https://doi.org/10.1182/blood-2016-01-691162

Published: 2016

Includes: Supplemental data

Journal Articles

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells

Blood (2016) 127 (9): 1138–1150.

https://doi.org/10.1182/blood-2015-06-649970

Published: 2016

Includes: Supplemental data

Journal Articles

A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia

Michele Cea, MD, Antonia Cagnetta, MD, Davide Lovera, MD, Raffaella Grasso, PhD, Nicoletta Colombo, PhD, Micaela Bergamaschi, MD, Sara Aquino, MD, Fabio Guolo, MD, Paola Minetto, MD, Filippo Ballerini, MD, Letizia Canepa, MD, Sophia Adamia, PhD, Alessio Nencioni, Ivana Pierri, MD, Marino Clavio, Maurizio Miglino, PhD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD

Blood (2015) 126 (23): 1375.

https://doi.org/10.1182/blood.V126.23.1375.1375

Published: 2015

NARROW

Excellent Outcome in NPM1- mutated Acute Myeloid Leukemia Patients Receiving Intensified Fludarabine-Based Induction Is Not Affected By Secondary Type Mutations and Other High Risk Aberrations

Deciphering the Immune Microenvironment in Waldenstrom's Macroglobulinemia

High Efficacy and Feasibility of a Full Pediatric Induction in Adults Aged up to 55 Years with Philadelphia-Negative Acute Lymphoblastic Leukemia

Mutational Burden in High Risk Genes Do Not Affect Remission Rates and MRD Clearance in Elderly AML Patients Receiving CPX-351 Induction

Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

Clonal Hematopoiesis: Exploiting Molecular Landscape of Multiple Myeloma Patients for Choosing the Most Appropriate Therapeutic Strategy

The Multi-Kinases Inhibitor ARQ531 Enhanches Anti-MM Activity of Imids By Dual Deregulation of MAP- and Cyclin-Dependent Kinases Activities

Prognostic Relevance of Minimal Residual Disease in Therapy Related and Secondary Acute Myeloid Leukemia Receiving CPX-351 or Fludarabine-Based Induction

Prognostic Impact of Minimal Residual Disease Assessment in Elderly Patients with Secondary Acute Myeloid Leukemia. a Comparison between CPX-351 and Intensified Fludarabine-Based Regimens

Addition of the Anti-CD33 Monoclonal Antibody Mylotarg to Fludarabine/High Dose Cytarabine - Based Induction Significantly Improves Outcome in Patient Affected By FLT3-ITD Positive Cytogenetically Normal Acute Myeloid Leukemia

A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML

Erwinia Chrysantemi-Derived L-Asparaginase Strongly Enhances Proteasome Inhibitors Activity By Deregulating Cell Metabolic Programs

Role of Erythropoietin in the Late Anemia of Patients with Chronic Myeloid Leukemia Treated Frontline with Imatinib

Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information

Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors

SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia

CD38 Deregulation As Strategy to Make Multiple Myeloma Cells More Sensitive to NAD+ Depleting Agents

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells

A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only